Travere Therapeutics, Inc. TVTX Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s other accrued liabilities?
- Travere Therapeutics, Inc. (TVTX) reported other accrued liabilities of $2.1M in Q1 2026.
- How has Travere Therapeutics, Inc.'s other accrued liabilities changed year-over-year?
- Travere Therapeutics, Inc.'s other accrued liabilities decreased by 86.7% year-over-year, from $15.76M to $2.1M.
- What is the long-term trend for Travere Therapeutics, Inc.'s other accrued liabilities?
- Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s other accrued liabilities has grown at a -11.8% compound annual growth rate (CAGR), from $5.98M to $3.19M.
- What does other accrued liabilities mean?
- This captures miscellaneous short-term obligations that do not fit into standard categories like accounts payable or accrued compensation. It often includes items such as customer deposits, short-term tax provisions, or other minor contractual liabilities. It provides insight into the breadth of the company's short-term financial commitments.